A rare case of ligamentum flavum cyst of the lumbar spine in an elderly male is reported. The patient presented with low backache and features of bilateral radiculopathy of a sudden onset. The cyst was lying in the extradural space. After surgery, the patient reported complete relief of symptoms.
Cystic hygroma is a benign, painless loculated lymphatic proliferation, which occur due to a combination of sequestration from developing lymphatic system, abnormal budding of the lymphatic system or lack of development of the normal connections between venous and lymphatic drainage. We report a case of giant cervico-thoracic cystic hygroma in a preterm neonate with management options and a brief review of literature.
The term, fibro-osseous lesions, is used for a group of pathological disturbances encompassing developmental, reactive or dysplastic lesions and neoplasms characterized by replacement of normal bone architecture by tissue composed of collagen fibers and fibroblasts containing various amount of calcified tissue. The groups of the fibro-osseous lesions are best considered as a spectrum of processes arising from cells in the periodontal ligament. Juvenile ossifying fibroma (JOF) is a benign, but potentially aggressive, fibro-osseous tumor of the craniofacial bones. This uncommon neoplasm is distinguished from other fibro-osseous lesions primarily by its age of onset, clinical presentation, potential behavior and the high tendency to recur. Clinically presenting as an actively growing lesion. Histopathologically consists cell rich fibrous stroma containing bands of cellular osteoid without osteoblastic lining together with trabeculae of more typical woven bone. Pathogenesis of JOF may be related to mutations of HRPT2 gene which may arises due to haploinsufficiency of the HRPT2 gene.
Here, we reported a case of trabecular JOF (TJOF) which had variations in clinical, radiographic features and histopathological characteristics and it's etiopathogenesis in detail.
How to cite this article
Kadam R, Patel S, Pathak J, Swain N, Kumar S. Trabecular Juvenile Ossifying Fibroma of the Craniofacial Skeleton: Etiopathogenesis and a Case Report of the Rare Entity. J Contemp Dent 2014;4(1):51-55.
Objective: To evaluate whether preterm neonates less than 34 weeks at birth receiving rapid enteral feeding advancement at 25-30 ml/kg/day and those receiving slow enteral feeding advancement at 15-20 mL⁄kg⁄day to attain full feeding (180 ml/kg/day) are atincrease in the incidence of necrotizing enterocolitis or feed intolerance.Study design: Retrospective cohort study.Setting: Level III Neonatal Unit in Southern India Subjects: Neonates born at <34 weeks of gestational age and admitted to the NICU during study period were enrolled.Outcome: Mortality and major morbidity -NEC as per Bell staging, incidence of feedintolerance.
Results:Both groups had similar baseline characteristics. The average gain in weight, length and head circumference were significantly lower in the slow feeding group as compared rapid feeding group. The mean days to reach birth weight was less in rapid feeding group; 12.43 vs. 15.46 in slow feeding group (p=0.04). It was inferred that duration of hospital stay (22.58 vs. 31.34 days) and parenteral nutrition( 8.69 vs. 11.18 days) was less in rapid feeding group as compared to slow feeding group (p= 0.04). Powered by Editorial Manager ® and ProduXion Manager® from Aries Systems Corporation Rapid feeding group does not have increased episodes of feed intolerance or NEC (5 vs. 6 cases) compared to slow feeding group.Conclusions: Our study support enteral nutrition by rapid enteral feeding regimen (increments of 25-30 ml⁄ kg ⁄day) in stable preterm neonates less than 34 weeks of gestation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.